Mechanistic sampling of intestinal tissue during this trial would best validate the reparative hypothesis if analyses include tight junction protein expression (e.g., claudins, occludin, zonula occludens-1), histologic healing assessments using validated indices (e.g., Geboes score, Robarts Histopathology Index), and intestinal permeability assays such as the lactulose-mannitol ratio
Potential side effects Common side effects include mild to moderate digestive issues like nausea and constipation, especially when first starting treatment
Occasional nausea returning during stress or after dietary indiscretion represents normal medication response rather than new concern
Therapeutic treatment with Ibrutinib attenuates imiquimod-induced psoriasis-like inflammation in mice through downregulation of oxidative and inflammatory mediators in neutrophils and dendritic cells
Do not start at the 0.5mg dose without completing the 0.25mg titration period
If one does, that is information too